Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2125 of 2529 entries
View as:

Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT01171976 Org: User:
Start: 09/30/10 End: 04/30/13 Due: 04/30/14

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Phase: N/A Priority: Normal
NCT ID: NCT01392443 Org: User:
Start: 10/14/10 End: 10/31/17 Due: 10/31/18

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase: N/A Priority: Normal
NCT ID: NCT04729387 Org: User:
Start: 07/22/21 End: 06/04/25 Due: 06/04/26

A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP

Phase: N/A Priority: Normal
NCT ID: NCT04346654 Org: User:
Start: 10/09/20 End: 09/22/23 Due: 09/22/24

A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

Phase: N/A Priority: Normal
NCT ID: NCT04929249 Org: User:
Start: 06/25/21 End: 09/15/23 Due: 09/15/24

A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study)

Phase: N/A Priority: Normal
NCT ID: NCT05758402 Org: User:
Start: 10/20/22 End: 06/30/23 Due: 06/30/24

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT04209205 Org: User:
Start: 01/29/20 End: 05/17/22 Due: 05/17/23

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03568461 Org: User:
Start: 11/12/18 End: 05/13/25 Due: 05/13/26

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Phase: N/A Priority: Normal
NCT ID: NCT03400176 Org: User:
Start: 04/09/18 End: 09/29/23 Due: 09/29/24

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

Phase: N/A Priority: Normal
NCT ID: NCT00929968 Org: User:
Start: 06/30/09 End: - Due: -

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

Phase: N/A Priority: Normal
NCT ID: NCT00124748 Org: User:
Start: 06/30/05 End: 11/30/10 Due: 11/30/11

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01514461 Org: User:
Start: 07/31/12 End: 05/31/14 Due: 05/31/15

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

Phase: N/A Priority: Normal
NCT ID: NCT01870778 Org: User:
Start: 10/02/13 End: 02/01/17 Due: 02/01/18

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

Phase: N/A Priority: Normal
NCT ID: NCT00402909 Org: User:
Start: 11/30/06 End: 08/31/07 Due: 08/31/08

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00613171 Org: User:
Start: 01/02/08 End: 01/13/10 Due: 01/13/11

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01691807 Org: User:
Start: 01/31/13 End: 12/31/15 Due: 12/31/16

An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

Phase: N/A Priority: Normal
NCT ID: NCT05368818 Org: User:
Start: 12/07/20 End: 05/06/21 Due: 05/06/22

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Phase: N/A Priority: Normal
NCT ID: NCT01491932 Org: User:
Start: 03/31/12 End: 10/31/13 Due: 10/31/14

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)

Phase: N/A Priority: Normal
NCT ID: NCT03377426 Org: User:
Start: 10/19/18 End: 10/28/19 Due: 10/28/20

Study of Out of Specification for Tisagenlecleucel

Phase: N/A Priority: Normal
NCT ID: NCT04094311 Org: User:
Start: 11/21/19 End: 03/31/26 Due: 03/31/27

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Phase: N/A Priority: Normal
NCT ID: NCT05703516 Org: User:
Start: 06/12/23 End: 10/31/26 Due: 10/31/27

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Phase: N/A Priority: Normal
NCT ID: NCT06649110 Org: User:
Start: 10/24/24 End: 09/03/26 Due: 09/03/27

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Phase: N/A Priority: Normal
NCT ID: NCT00564941 Org: User:
Start: 12/31/07 End: 07/31/11 Due: 07/31/12

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF

Phase: N/A Priority: Normal
NCT ID: NCT02007720 Org: User:
Start: 03/12/14 End: 06/16/17 Due: 06/16/18

Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00241020 Org: User:
Start: 06/30/02 End: 10/31/05 Due: 10/31/06